Wirkung des standardisierten japanischen Kampo-Arzneipflanzenpräparates Juzentaihoto auf das Tumormikroenvironment des Pankreaskarzinoms – ein Vergleich mit Gemcitabin

Siebel, Anna Paulina

dc.contributor.advisor	Cameron, Silke PD Dr.
dc.contributor.author	Siebel, Anna Paulina
dc.date.accessioned	2025-02-24T10:24:01Z
dc.date.issued	2025-02-24
dc.identifier.uri	http://resolver.sub.uni-goettingen.de/purl?ediss-11858/15840
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-11104
dc.format.extent	100	de
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc	610	de
dc.title	Wirkung des standardisierten japanischen Kampo-Arzneipflanzenpräparates Juzentaihoto auf das Tumormikroenvironment des Pankreaskarzinoms – ein Vergleich mit Gemcitabin	de
dc.type	doctoralThesis	de
dc.title.translated	Effect of the standardized Japanese Kampo Extract Juzen-taiho-to on the Tumor microenvironment in a Pancreatic cancer mouse model – a comparison to Gemcitabine	de
dc.contributor.referee	Napp, Joanna Dr.
dc.date.examination	2025-03-20	de
dc.description.abstracteng	Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive gastrointestinal malignancies, characterized by poor prognosis and limited therapeutic success. Despite surgical resection being the sole curative approach, the high recurrence rate and late-stage diagnosis necessitate innovative therapeutic strategies. This study investigates the immunomodulatory effects of the standardized Japanese herbal medicine Juzentaihoto (JUZ) alone and in combination with gemcitabine, a standard chemotherapeutic agent, in an orthotopic pancreatic cancer mouse model and in vitro settings. The findings demonstrate that JUZ promotes M1 macrophage polarization, enhancing anti-tumor immune responses, while improving the efficacy of gemcitabine by mitigating its resistance. Additionally, JUZ significantly modulates the tumor microenvironment and cytokine expression, resulting in prolonged survival in treated groups. These results underline the potential of JUZ as an adjuvant therapy for PDAC, emphasizing the need for further molecular investigations and clinical trials to validate its application.	de
dc.contributor.coReferee	Meyer, Thomas Prof. Dr.
dc.subject.ger	Kampo Medizin	de
dc.subject.ger	Juzentaihoto	de
dc.subject.ger	Gemcitabin	de
dc.subject.ger	Duktales Pankreaskarzinom	de
dc.subject.ger	Makrophagen	de
dc.subject.ger	Tumormikroenvironment	de
dc.subject.eng	Pancreatic ductal adenocarcinoma (PDAC)	de
dc.subject.eng	Kampo medicine	de
dc.subject.eng	Juzentaihoto	de
dc.subject.eng	Gemcitabine	de
dc.subject.eng	orthotopic transplantation PDAC mouse model	de
dc.subject.eng	murine KPC pancreatic tumor cells	de
dc.subject.eng	macrophages	de
dc.subject.eng	tumor microenvironment	de
dc.identifier.urn	urn:nbn:de:gbv:7-ediss-15840-7
dc.date.embargoed	2025-04-24
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Komplementärmedizin - Allgemein- und Gesamtdarstellungen (PPN619876530)	de
dc.description.embargoed	2025-04-24	de
dc.identifier.ppn	1918568421
dc.notes.confirmationsent	Confirmation sent 2025-02-24T10:45:02	de

Files in this item

Name:2025_02_06_Siebel_Anna Paulina_Dissertation_ohne Lebenslauf.pdf

Size:36.42Mb

Format:PDF

View/Open

Name:: 2025_02_06_Siebel_Anna Paulina ...
Size:: 36.42Mb
Format:: PDF

View/Open

This item appears in the following Collection(s)

Human- und Zahnmedizin [3204]

Show simple item record